{"id":5767,"date":"2023-04-03T13:00:00","date_gmt":"2023-04-03T11:00:00","guid":{"rendered":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/hor-stayble-therapeutics-abs-vd-presentera-bolaget-och-foretradesemissionen\/"},"modified":"2023-04-03T13:00:00","modified_gmt":"2023-04-03T11:00:00","slug":"hor-stayble-therapeutics-abs-vd-presentera-bolaget-och-foretradesemissionen","status":"publish","type":"cision-feed","link":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/hor-stayble-therapeutics-abs-vd-presentera-bolaget-och-foretradesemissionen\/","title":{"rendered":"H\u00f6r Stayble Therapeutics AB:s VD presentera bolaget och f\u00f6retr\u00e4desemissionen"},"content":{"rendered":"<p style=\"margin-bottom:0pt;margin-top:12px\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\"><strong>Fill or Kill podcast,<\/strong><\/span><span style=\"color:#242424;font-family:arial,helvetica,sans-serif;font-size:11pt\"><strong>&nbsp;<\/strong><\/span><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">28 mars 2023. VD Andreas Gerward medverkar i en intervju i podcasten Fill or Kill. Avsnittet publiceras via vedertagna svenska podcast-applikationer och webbtj\u00e4nster, exempelvis Spotify, samt g\u00e5r att h\u00f6ra p\u00e5 Staybles webbsida om f\u00f6retr\u00e4desemissionen <\/span><a href=\"https:\/\/www.foretradesemission.staybletherapeutics.se\/\" style=\"text-decoration:none\" target=\"_blank\" rel=\"noopener\"><span style=\"color:#3b3838;font-family:arial,helvetica,sans-serif;font-size:9pt\">https:\/\/www.foretradesemission.staybletherapeutics.se\/<\/span><\/a><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\"><strong>Investerarm\u00f6tet med Financial Stockholm<\/strong><\/span><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">, var den 29 mars 2023 kl.17:25-21:00. Se presentationen p\u00e5 f\u00f6ljande <\/span><a href=\"https:\/\/www.youtube.com\/watch?v=6dTiXpFKmpM\" style=\"text-decoration:none\"><span style=\"color:#0000ff;font-family:arial,helvetica,sans-serif;font-size:9pt\"><u>l\u00e4nk<\/u><\/span><\/a><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">. <\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\"><strong>Finwire VD intervju,<\/strong><\/span><span style=\"color:#242424;font-family:arial,helvetica,sans-serif;font-size:11pt\"><strong>&nbsp;<\/strong><\/span><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\"> Andreas Gerward intervjuas av Finwire.<\/span><span style=\"color:#242424;font-family:arial,helvetica,sans-serif;font-size:11pt\">&nbsp;<\/span><span style=\"color:#000000;font-family:arial,helvetica,sans-serif;font-size:9pt\">Intervjun kommer att g\u00f6ras tillg\u00e4nglig den 3:e april via f\u00f6ljande <\/span><a href=\"https:\/\/www.youtube.com\/watch?v=JddZyK7TYr4\" style=\"text-decoration:none\"><span style=\"color:#0000ff;font-family:arial,helvetica,sans-serif;font-size:9pt\"><u>l\u00e4nk<\/u><\/span><\/a><\/p>\n<h4 style=\"margin-bottom:0pt;margin-top:2pt\"><span style=\"color:#0f0d29;font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/h4>\n<p style=\"font-family:arial,helvetica,sans-serif;margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<h2 style=\"font-size:14pt;margin-bottom:6pt;margin-top:0pt;text-align:left\"><span style=\"color:#305584;font-family:arial,helvetica,sans-serif;font-size:9pt;font-weight:normal\">F\u00f6r mer information<\/span><\/h2>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\"><strong>F\u00f6r mer information om Stayble, v\u00e4nligen kontakta:<\/strong><\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Andreas Gerward, VD Stayble Therapeutics AB<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">E-post: andreas.gerward@stayble.se <\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Telefon: +46 730 808<\/span><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">397<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<h2 style=\"font-size:14pt;margin-bottom:6pt;margin-top:0pt;text-align:left\"><span style=\"color:#305584;font-family:arial,helvetica,sans-serif;font-size:9pt;font-weight:normal\">Om Stayble Therapeutics AB<\/span><\/h2>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Stayble \u00e4r ett kliniskt l\u00e4kemedelsbolag som utvecklar injektionsbehandlingen STA363 mot degenerativ disksjukdom (DDD) och kroniskt diskbr\u00e5ck (LDH). Staybles vision \u00e4r att kunna erbjuda patienter en enkel och effektiv behandling som angriper den underliggande orsaken till patientens kroniska sm\u00e4rta och ger varaktig sm\u00e4rtlindring och \u00f6kad fysisk funktion. Behandlingen riktar sig till patienter som inte blir hj\u00e4lpta av sjukgymnastik och sm\u00e4rtstillande preparat och \u00e4r en singelinjektion som ber\u00e4knas kvarst\u00e5 hela livet och kr\u00e4ver minimal rehabilitering. Bolaget har nu fokus p\u00e5 den fortsatta kliniska utvecklingen och genomf\u00f6r just nu en klinisk fas 2b-studie inom DDD och en fas Ib-studie inom LDH. <\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Bolagets Certified Adviser \u00e4r Svensk Kapitalmarknadsgranskning AB.<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Med anledning av den p\u00e5g\u00e5ende f\u00f6retr\u00e4desemissionen av aktier g\u00f6r Stayble Therapeutics VD Andreas Gerward ett antal presentationer och intervjuer. Mer information om f\u00f6retr\u00e4desemissionen, d\u00e4r teckningstiden p\u00e5g\u00e5r fram till den 12 april, se https:\/\/www.foretradesemission.staybletherapeutics.se\/<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5767"}],"collection":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed"}],"about":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/cision-feed"}],"replies":[{"embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/comments?post=5767"}],"version-history":[{"count":0,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5767\/revisions"}],"wp:attachment":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=5767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}